223 related articles for article (PubMed ID: 36189319)
1. Landscape of prognosis and immunotherapy responsiveness under tumor glycosylation-related lncRNA patterns in breast cancer.
Lv W; Tan Y; Zhou X; Zhang Q; Zhang J; Wu Y
Front Immunol; 2022; 13():989928. PubMed ID: 36189319
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Tumor Glycosylation Characteristics and Implications for Immune Checkpoint Inhibitor's Efficacy for Breast Cancer.
Lv W; Yu H; Han M; Tan Y; Wu M; Zhang J; Wu Y; Zhang Q
Front Immunol; 2022; 13():830158. PubMed ID: 35444644
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
4. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
5. Construction and validation of a transient receptor potential-related long noncoding RNA signature for prognosis prediction in breast cancer patients.
Guo Q; Qiu P; Pan K; Chen J; Wang B; Lin J
Medicine (Baltimore); 2023 Nov; 102(46):e35978. PubMed ID: 37986367
[TBL] [Abstract][Full Text] [Related]
6. An exosome-related long non-coding RNAs risk model could predict survival outcomes in patients with breast cancer.
Qiu P; Guo Q; Lin J; Pan K; Chen J; Ding M
Sci Rep; 2022 Dec; 12(1):22322. PubMed ID: 36566321
[TBL] [Abstract][Full Text] [Related]
7. Identification of cuproptosis-related long noncoding RNA signature for predicting prognosis and immunotherapy response in bladder cancer.
Huang G; Huang Y; Zhang C; Jiang Y; Ye Z; He C; Yu F; Chen Z; Xi X
Sci Rep; 2022 Dec; 12(1):21386. PubMed ID: 36496537
[TBL] [Abstract][Full Text] [Related]
8. Necroptosis-related lncRNA to establish novel prognostic signature and predict the immunotherapy response in breast cancer.
Chen F; Yang J; Fang M; Wu Y; Su D; Sheng Y
J Clin Lab Anal; 2022 Apr; 36(4):e24302. PubMed ID: 35229919
[TBL] [Abstract][Full Text] [Related]
9. A genomic instability-related lncRNA model for predicting prognosis and immune checkpoint inhibitor efficacy in breast cancer.
Jiao Y; Li S; Wang X; Yi M; Wei H; Rong S; Zheng K; Zhang L
Front Immunol; 2022; 13():929846. PubMed ID: 35990656
[TBL] [Abstract][Full Text] [Related]
10. A new risk model based on a 11-m
Lei L; Li N; Yuan P; Liu D
BMC Cancer; 2022 Apr; 22(1):365. PubMed ID: 35382776
[TBL] [Abstract][Full Text] [Related]
11. Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune-related lncRNA.
Shen S; Chen X; Hu X; Huo J; Luo L; Zhou X
Cancer Med; 2021 Sep; 10(18):6561-6575. PubMed ID: 34378851
[TBL] [Abstract][Full Text] [Related]
12. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
13. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
Fan CN; Ma L; Liu N
J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
15. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers.
Peng L; Chen Z; Chen Y; Wang X; Tang N
Cancer Med; 2019 Dec; 8(17):7161-7173. PubMed ID: 31568700
[TBL] [Abstract][Full Text] [Related]
16. Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma.
Zhang Y; Zhang L; Xu Y; Wu X; Zhou Y; Mo J
J Cell Physiol; 2020 Dec; 235(12):9304-9316. PubMed ID: 32330311
[TBL] [Abstract][Full Text] [Related]
17. Emerging glyco-risk prediction model to forecast response to immune checkpoint inhibitors in colorectal cancer.
Qiu P; Chen X; Xiao C; Zhang M; Wang H; Wang C; Li D; Liu J; Chen Y; Liu L; Zhao Q
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6411-6434. PubMed ID: 36757621
[TBL] [Abstract][Full Text] [Related]
18. Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer.
Hui P; Ni F; Zheng L; Jia L; Wang Z
BMC Cancer; 2023 Apr; 23(1):355. PubMed ID: 37072750
[TBL] [Abstract][Full Text] [Related]
19. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
[TBL] [Abstract][Full Text] [Related]
20. Prognostic model based on m6A-associated lncRNAs in esophageal cancer.
Wang W; Dong D; Yu P; Chen T; Gao R; Wei J; Mo Z; Zhou H; Yang Q; Yue C; Yang X; Li X; Ji G
Front Endocrinol (Lausanne); 2022; 13():947708. PubMed ID: 36111294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
